Swiss contract drugmaker Lonza plans to exit its capsules and health ingredients (CHI) business, it said on Thursday, after ...

The life-sciences company will focus on its core business, including drug development, with restructuring and a divestment ...

Lonza Group AG / Key word (s): Strategic Company Decision Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance 12-Dec-2024 / 06:25 CET/CEST Release of an ad hoc ...

Swiss healthcare manufacturing organization Lonza saw its shares rise 7% to 559.40 francs in early trading, as it announced ...

Investing.com -- Lonza’s shares rose over 6% on Thursday following the company’s announcement of plans to divest its Capsules ...

Lonza Group Ltd (GB:0QNO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

Delivering biologics via oral administration represents a growing market that is expected to exhibit 35% CAGR from 2023–2028.

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at its Visp, Switzerland, plant. The expansion, which should go live in 2028 ...

Lonza Group AG (OTCMKTS:LZAGY – Free Report) – William Blair lowered their FY2025 EPS estimates for Lonza Group in a research ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Redburn Atlantic analyst Jamie Clark initiated coverage of Lonza (LZAGY) with a Buy rating and CHF 650 price target Lonza, as the world’s largest contract development and manufacturing ...